VSport(Öйú) - ʤÀûÒòÄú¸ü¾«²Ê

ÕªÒª

CTC¸»¼¯¼¼ÊõÊÇCTCÑо¿µÄ»ù´¡£¬Ò²ÊÇCTCÑо¿µÄÖصãºÍÄѵã¡£±¾ÎľÍCTC EpCAMÑôÐÔ¸»¼¯¼¼ÊõÓëÒõÐÔ¸»¼¯¼¼ÊõµÄ½øÐÐÖصã±È½Ï£¬ÒÔ»ùÓÚϸ°ûϵspike-inÑù±¾ºÍÁÙ´²Ñù±¾µÄÍ·¶ÔÍ·±È½Ï£¬ÏÔʾ¶Ù»ÛVsport²ÉÈ¡µÄEpCAMÒõÐÔ¸»¼¯¼¼ÊõÕ¹ÏÖ³ö¸ü¼ÑµÄÁéÃô¶ÈºÍ¼ì³öÂÊ£¬ÔÚCTC¸»¼¯ºÍ¼ì²âÖоßÓиüÏÔÖøµÄÓÅÊÆ¡£

CTC×÷ΪҺÌå»î¼ìµÄÖØÒª±êÖ¾ÎÔÚÁÙ´²ÖоßÓй㷺µÄÓ¦ÓüÛÖµ¡£È»¶ø£¬CTCµÄÁÙ´²Ó¦ÓÃÒÀÈ»ÃæÁÙ²»Ð¡µÄÌôÕ½£¬¾ßÌå°üÀ¨Ï¸°ûŨ¶ÈµÍ¡¢Ï¸°ûÒ×½µ½â¡¢Ï¸°ûÄѼø±ðµÈ¡£CTCµÄÐÎ̬Óë°×ϸ°ûÀàÐÍ£¬½ö´ÓÐÎ̬½Ç¶È¼ÓÒÔÇø±ðÏÔÈ»ÓÐʧƫÆÄ£¬È»ºóCTCÓÖ¾ßÓи߶ȵÄÒìÖÊÐÔ£¬³£³£·¢Éú±íƤ¼ä³äÖÊ»¯£¨EMT£©µÈ^[1]£¬Õâ¸øCTCµÄ¸»¼¯ºÍ¼ø¶¨Ìá³öÁ˲»Ð¡µÄÄÑÌâ¡£

01. CTC¸»¼¯ºÍ¼ø¶¨µÄ·½·¨Ñ§

CTCµÄ¸»¼¯Ö÷Òª»ùÓÚÆäÎïÀíѧºÍÉúÎïѧÌØÐÔ½øÐУ¬°üÀ¨ÎïÀíÌØÐÔ·ÖÀë·¨¡¢ÃâÒßÇ׺͸»¼¯·¨ÒÔ¼°»ùÓÚϸ°ûµÄÎïÀíºÍÉú»¯ÐÔÖʵÄÁªºÏ·ÖÀë·¨µÈ^[2]¡£ÔÚ¹ýÈ¥µÄ¼¸ÄêÀ΢Á÷¿Ø¼¼Êõ×÷Ϊ»ùÓÚÎïÀíѧÌØÐÔ¸»¼¯µÄ·½·¨±»¹ã·ºÊ¹ÓÃ^[3,4]£¬¶ø½ü¼¸Äê»ùÓÚ±ê¼Ç¸»¼¯µÄCTC¸»¼¯¼¼ÊõÔò¸üΪÖ÷Á÷¡£Ä¿Ç°FDAΨһ»ñÅúµÄCTC¼ì²âƽ̨ÊÇCellSearch£¬CellSearchÊÇÒ»ÀàÒÀ¾Ýϸ°û±íÃæµ°°×EpCAMµÄ¿¹Ìå½øÐи»¼¯µÄ·½·¨^[5]¡£

È»¶ø£¬Óв»ÉÙÑо¿±íÃ÷£¬CTCϸ°û¾ßÓÐEMTÌØÐÔ£¬EpCAM±í´ï´ó´ó½µµÍ¡£ÀýÈ磬ͼ1AÕë¶Ô4¸öÇ°ÁÐÏÙ°©Ï¸°ûϵµÄEpCAMºÍEMT marker VimentinµÄÁ÷ʽ½á¹ûÏÔʾ£¬PC-3ºÍPC-3MµÄVimentin¸ß±í´ï£¬EpCAMµÄ±í´ïÔò´ó´óϽµ^[6]£»Í¼1BÕë¶Ôθ°©»¼ÕßµÄCTC½øÐÐEpCAMºÍEMT marker VimentinµÄ¶àÉ«ÃâÒßÓ«¹âÏÔʾ´æÔÚEpCAM-µÄ¼ä³äÖÊÐÍCTC^[7]£»Í¼1CÕë¶ÔÈéÏÙ°©»¼ÕßµÄCTCµÄ¶àÉ«ÃâÒßÓ«¹âͬÑùÖ§³Ö´æÔÚEpCAM-µÄ¼ä³äÖÊÐÍCTC^[8]£»Í¼1DÕë¶ÔÂѳ²°©»¼Õ߸¹Ë®µÄCTCµÄµ¥Ï¸°û²âÐò½á¹û½øÐзÖÎöÏÔʾ£¬´æÔÚEpCAM+ºÍEpCAM-Á½ÀàCTC^[9,10]£»Í¼1EÕë¶ÔÒÈÏÙ°©¸ÎתÒÆ»¼ÕßµÄÔ­·¢ÔתÒÆÔîºÍÍâÖÜѪ¸»¼¯µÄCTC½øÐе¥Ï¸°û²âÐò½á¹ûÏÔʾ£¬CTC½ÏÔ­·¢ÔîºÍתÒÆÔîµÄÖ×Áöϸ°ûÏà±È£¬EpCAMµÄ±í´ï´ó´óϽµ^[11]¡£EpCAMÔÚ·º°©ÖÖµÄCTCÖеıí´ïˮƽµÄ¶àÑùÐÔÏÔʾ½ö¾ÖÏÞÓÚEpCAMµÄÑôÐÔ¸»¼¯¿ÉÄÜ»áÔì³É´óÁ¿µÄ¼ÙÒõÐÔ£¬¶ÔÓÚCTC¸»¼¯µÄ¼¼Êõ£¬¿ÉÄÜÐèÒª³ÖÓиü¶àÔª¸ü½÷É÷µÄ̬¶È¡£

ͼ1. CTCµÄEpCAM±í´ï¶àÑùÐÔ

02. ¶Ù»ÛVsportµÄEpCAMÒõÐÔ¸»¼¯²ßÂÔ

Ϊ½â¾öEpCAMÒìÖÊÐÔ¶ÔCTC¸»¼¯µÄ²»Á¼Ó°Ï죬¶Ù»ÛVsportÓ븴µ©´óѧ£¨¸½ÊôÖÐɽҽԺ£©¸Î°©Ñо¿Ëù·®¼ÎԺʿ¡¢ÑîÐÀÈÙ½ÌÊÚºÏ×÷¿ª·¢µÄÈ«×Ô¶¯µÄ»ùÓÚEpCAMÒõÐÔ¸»¼¯Æ½Ì¨£¬°üº¬ÒõÐÔ¸»¼¯¡¢ÃâÒßÓ«¹â±ê¼ÇºÍ»ùÓÚ»úÆ÷ѧϰµÄCTCʶ±ðµÈ²½Ö裬¸»¼¯µÄCTC¿ÉÓÃÓÚµ¥Ï¸°ûת¼×é²âÐò¡¢»ùÒò×é²âÐò¡¢µ°°××éѧ·ÖÎöµÈ¶à×éѧÑо¿£¬´ó´óÀ©Õ¹ÁËCTCµÄÁÙ´²ºÍ¿ÆÑÐÓ¦Óã¬Ïà¹ØÑо¿·¢±íÓÚMolecular OncologyÔÓÖ¾^[12]¡£

¶Ù»ÛVsportËù²ÉÓõÄEpCAMÒõÐÔ¸»¼¯ºÍʶ±ð²ßÂÔµÄÓÅÊÆÔÚÓÚ£º

1. ¿Ë·þÁËEpCAM±í´ïÒìÖÊÐÔÒýÆðµÄ¼ÙÒõÐÔ£¬´ó´óÌá¸ßÁ˼ì³öÂÊ¡£

2. »ùÓÚ¸ßά¶ÈÐÅϢץȡµÄͼÏñʶ±ð»ñȡϸ°ûÐÅÏ¢£¬¸ü´óÏ޶ȵظ»¼¯CTC£¬½µµÍÁ˼ÙÒõÐÔ£¬´ó´óÌá¸ßÁ˼ì³öÂÊ¡£

3. »ùÓÚÈ˹¤ÖÇÄܵĻúÆ÷ѧϰʶ±ðϸ°û£¬¸ü´óÏ޶ȵØ׼ȷʶ±ðCTC£¬½µµÍÁ˼ÙÑôÐԺͼÙÒõÐÔ£¬Ìá¸ßÁËCTCʶ±ðµÄ׼ȷÐÔ¡£

Ϊ½øÒ»²½ÑéÖ¤ÉÏÊöÓÅÊÆ£¬¸ÃÑо¿½«4ÖÖEpCAM±í´ï¸÷ÒìµÄϸ°ûϵÒÔ²»Í¬Å¨¶È¼ÓÈëµ½ÍâÖÜѪÑù±¾ÖУ¨Í¼2A£©£¬ÓëCellSearchƽ̨½øÐÐÍ·¶ÔÍ·±È½Ï£¬ÆäÖÐEpCAMÖС¢µÍ±í´ïµÄHepG2£¬SkBr3ºÍT24ϸ°ûϵÏÔÖø¸ßÓÚCellSearchƽ̨µÄ»ØÊÕÂÊ£¨Í¼2B£©£¬Í¹ÏÔÁ˶ٻÛVsportµÄÒõÐÔ¸»¼¯²ßÂÔÔÚEpCAMÖС¢µÍ±í´ïÑù±¾Öеļì³öÓÅÊÆ¡£Õë¶ÔÒìÖÊÐÔ¸ü¸ßµÄÁÙ´²Ñù±¾£¬¶Ù»ÛVsportµÄÒõÐÔ¸»¼¯²ßÂÔ³ÊÏÖ¸ü¸ßµÄ¼ì³öÂÊ£¨Í¼2C£©¡£

ͼ2. EpCAMÒõÐÔ¸»¼¯²ßÂÔºÍEpCAMÑôÐÔ¸»¼¯²ßÂÔÐÔÄܱȽÏ

С½á

¼øÓÚCTCµÄ¸ß¶ÈÒìÖÊÐÔ£¬ÁªºÏÒõÐÔ¸»¼¯ºÍ±íÃ濹ԭmarkerµÄ¼ø¶¨ÓÐÀûÓÚ¸ü´ó³Ì¶ÈµØ½µµÍϸ°ûËðʧºÍ½µµÍ¼ì²â¼ÙÒõÐÔ¡£¶Ù»ÛVsportµÄÒõÐÔ¸»¼¯²ßÂÔÕë¶ÔEpCAMÖС¢µÍ±í´ïˮƽµÄCTC¾ßÓиüÏÔÖøµÄ¼ì²âÐÔÄÜ£¬Òò´ËÒõÐÔ¸»¼¯¼¼ÊõÔÚCTC¸»¼¯ÖоßÓиüÏÔÖøµÄÓÅÊÆ¡£

²Î¿¼ÎÄÏ×£º 

[1], Naei et al., Advances in novel strategies for isolation, characterization, and analysis of CTCs and ctDNA. Ther Adv Med Oncol. 2023 Sep 7:15:17588359231192401.

[2], Banko et al., Technologies for circulating tumor cell separation from whole blood. J Hematol Oncol. 2019 May 14;12(1):48.

[3], Zhou et al., Isolation of circulating tumor cells in non-small-cell-lung-cancer patients using a multi-flow microfluidic channel. Microsyst Nanoeng. 2019 Feb 25:5:8.

[4], Warkiani et al., Ultra-fast, label-free isolation of circulating tumor cells from blood using spiral microfluidics. Nat Protoc. 2016 Jan;11(1):134-48.

[5], Riethdorf et al., Clinical applications of the Cell Search platform in cancer patients. Adv Drug Deliv Rev 125, 102¨C121.

[6],Lowes et al., Epithelial-to-mesenchymal transition leads to disease-stage differences in circulating tumor cell detection and metastasis in pre-clinical models of prostate cancer. Oncotarget. 2016 Nov 15;7(46):76125-76139.

[7],Hu et al., Epithelial-mesenchymal transition may be involved in the immune evasion of circulating gastric tumor cells via downregulation of ULBP1. Cancer Med. 2020 Apr;9(8):2686-2697.

[8], Guan et al., Epithelial-Mesenchymal-Transition-Like Circulating Tumor Cell-Associated White Blood Cell Clusters as a Prognostic Biomarker in HR-Positive/HER2-Negative Metastatic Breast Cancer. Front Oncol. 2021 Jun 2:11:602222.

[9], Izar et al., A single-cell landscape of high-grade serous ovarian cancer. Nat Med. 2020 Aug;26(8):1271-1279.

[10], Li et al., Genes (Basel). 2022 Dec 2;13(12):2276.

[11], Liu et al., Immune checkpoint HLA-E:CD94-NKG2A mediates evasion of circulating tumor cells from NK cell surveillance. Cancer Cell. 2023 Feb 13;41(2):272-287.e9.

[12], Wang et al., Circulating tumor cell detection and single-cell analysis using an integrated workflow based on ChimeraX?-i120 Platform: A prospective study. Mol Oncol. 2021 Sep;15(9):2345-2362.